Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Delbaldo

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2015
Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†C Delbaldo, M Ychou, A Zawadi, et al.
British Journal of Cancer|February 28, 2008
Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancerI Sobhani, E Tiret, R Lebtahi, et al.
ESMO Open|May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trialF Penault-Llorca, F Dalenc, S Chabaud, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2015
Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†C Delbaldo, M Ychou, A Zawadi, et al.
British Journal of Cancer|February 28, 2008
Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancerI Sobhani, E Tiret, R Lebtahi, et al.
ESMO Open|May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trialF Penault-Llorca, F Dalenc, S Chabaud, et al.
Pageof 2